Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)

NCT02640508 is registered in ClinicalTrials.gov with Virginia G. Kaklamani as lead sponsor.

NCT NCT02640508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02640508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)
Lead sponsor
Virginia G. Kaklamani
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2016
Completion date
January 12, 2023
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumor